Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Alemtuzumab and Dexamethasone in High-Risk CLL
NCT01392079Phase 2Completed
- Sponsor
- Ulm University
- Start
- Feb 2008
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Ulm University. Started Feb 2008; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01392079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392079.